SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis

References

• Schou Nielsen J, Meteran H, Ulrik CS, et al. Natural history of skin prick test reactivity: A 20-year prospective study of a random population sample of children and adolescents. Ann Allergy Asthma Immunol. 2017 Aug;119(2):184–188.e1.
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–958.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Fokkens WJ. Allergic rhinitis and its impact on otorhinolaryngology. Allergy. 2006 Jun;61(6):656–664.
   PubMed Web of Science ®Google Scholar
• Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am. 2016 May;36(2):235–248.
   PubMed Web of Science ®Google Scholar
• Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of Rhinitis on work productivity: a systematic review. The Journal of Allergy and Clinical Immunology in Practice. 2018 Aug;6(4):1274–1279.
   PubMed Web of Science ®Google Scholar
• Krouse JH. The unified airway–conceptual framework. Otolaryngol Clin North Am. 2008 Apr;41(2): 257–66–v.
   Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008 Sep 20;372(9643):1049–1057.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy. 2005 Jun;35(6):723–727.
   PubMed Web of Science ®Google Scholar
• Gandhi VD, Davidson C, Asaduzzaman M, et al. House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep. Current Science Inc. 2013 Jun;13(3):262–270.
   PubMed Web of Science ®Google Scholar
• Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011 Sep;32(9):402–411.
   PubMed Web of Science ®Google Scholar
• Linneberg A, Henrik Nielsen N, Frølund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The copenhagen allergy study. Allergy. 2002 Nov;57(11):1048–1052.
   PubMed Web of Science ®Google Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004 Nov;24(5):758–764.
   PubMed Web of Science ®Google Scholar
• Sala-Cunill A, Bartra J, Dalmau G, et al. Prevalence of asthma and severity of allergic rhinitis comparing 2 perennial allergens: house dust mites and Parietaria judaica pollen. J Investig Allergol Clin Immunol. 2013;23(3):145–151.
   PubMed Web of Science ®Google Scholar
• Blomme K, Tomassen P, Lapeere H, et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. Int Arch Allergy Immunol. 2013;160(2):200–207.
   PubMed Web of Science ®Google Scholar
• Arbes SJ, Gergen PJ, Elliott L, et al. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National health and nutrition examination survey. J Allergy Clin Immunol. 2005 Aug;116(2):377–383.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Shima M, Nakadate T, et al. Patterns of sensitization to inhalant allergens in Japanese lower-grade schoolchildren and related factors. Int Arch Allergy Immunol. 2015;167(4):253–263.
   PubMed Web of Science ®Google Scholar
• Li J, Sun B, Huang Y, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009 Jul;64(7):1083–1092.
   PubMed Web of Science ®Google Scholar
• Calderón M, Cardona V, Demoly P. EAACI 100 Years of immunotherapy experts panel. One hundred years of allergen immunotherapy European academy of allergy and clinical immunology celebration: review of unanswered questions. Allergy. 2012 Apr;67(4):462–476.
   PubMed Web of Science ®Google Scholar
• Durham SR. Mechanisms of mucosal inflammation in the nose and lungs. Clin Exp Allergy. 1998 Jun;28(Suppl 2):11–16.
   PubMedGoogle Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011 Jan;127(1):18–27–quiz28–9.
   Web of Science ®Google Scholar
• Van Ree R, Van Leeuwen WA, Dieges PH, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy. 1997 Jan;27(1):68–74.
   PubMed Web of Science ®Google Scholar
• Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005 Aug;116(2):347–354.
   PubMed Web of Science ®Google Scholar
• Aasbjerg K, Backer V, Lund G, et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy. 2014 Mar;44(3):417–428.
   PubMed Web of Science ®Google Scholar
• Pierkes M, Bellinghausen I, Hultsch T, et al. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):326–332.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015 Jul;136(1):38–48.
   PubMed Web of Science ®Google Scholar
• Ohashi-Doi K, Kito H, Du W, et al. Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation. Int Arch Allergy Immunol. 2017;174(1):26–34.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016 Dec;138(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018 Apr 12;9(1):1421.
   PubMedGoogle Scholar
• Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24(3):154–161.
   PubMed Web of Science ®Google Scholar
• Okamiya K, Sekino H, Azuma R, et al. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study. J Asthma. 2018 Nov;16(24):1–9.
   Google Scholar
• Maloney J, Prenner BM, Bernstein DI, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol. 2016 Jan;116(1):59–65.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015 Feb;114(2):134–140.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, De Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014 Sep;134(3):568–575.e7.
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015 Jun;135(6):1494–1496.
   PubMed Web of Science ®Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016 Feb;137(2):444–448.
   PubMed Web of Science ®Google Scholar
• Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol. 2017 Jun;139(6):1840–1848.e10.
   PubMed Web of Science ®Google Scholar
• Masuyama K, Okamoto Y, Okamiya K, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018 Dec;73(12):2352–2363.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016 Apr 26;315(16):1715–1725.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and safety of HDM SLIT-tablet in Japanese adults with allergic asthma. J Allergy Clin Immunol Pract. 2019 Sep; pii:S2213–2198(19)30779–2.
   Google Scholar
• Zieglmayer P, Nolte H, Nelson HS, et al. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Ann Allergy Asthma Immunol. 2016 Dec;117(6):690–691.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2003 Mar;111(3):484–490.
   PubMed Web of Science ®Google Scholar
• Camhi S, Morgan W, Pernisco N, et al. Factors affecting sleep disturbances in children and adolescents. Sleep Med. 2000 Apr 1;1(2):117–123.
   PubMed Web of Science ®Google Scholar
• de Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma–post hoc results from a randomised trial. Respir Med. 2014 Oct;108(10):1430–1437.
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011 Jan;127(1):64–71, 71.e1–4.
   PubMed Web of Science ®Google Scholar
• Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan;123(1):167.
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):146–153.e2.
   PubMed Web of Science ®Google Scholar
• Emminger W, Hernández MD, Cardona V, et al. The SQ House dust mite SLIT-tablet is well tolerated in patients with house dust mite respiratory allergic disease. Int Arch Allergy Immunol. 2017;174(1):35–44.
   PubMed Web of Science ®Google Scholar
• Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen-induced allergic rhinitis - differences between subcutaneous and sublingual treatment. Basic Clin Pharmacol Toxicol. 2015 Aug;117(2):73–84.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Kleine-Tebbe J, et al. Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round. The Journal of Allergy and Clinical Immunology in Practice. 2018 Oct;6(5):1758–1760.e1.
   PubMed Web of Science ®Google Scholar
• Björstad Å, Cardell L-O, Hahn-Pedersen J, et al. A cost-minimisation analysis comparing sublingual immunotherapy to subcutaneous immunotherapy for the treatment of house dust mite allergy in a Swedish Setting. Clin Drug Investig. 2017 Jun;37(6):541–549.
   PubMed Web of Science ®Google Scholar
• Rønborg S, Johnsen CR, Theilgaard S, et al. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark. J Med Econ. 2016 Aug;19(8):735–741.
   PubMed Web of Science ®Google Scholar
• Green W, McMaster J, Babela R, et al. Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries. Eur Ann Allergy Clin Immunol. 2019 Mar;51(2):68–74.
   PubMed Web of Science ®Google Scholar